Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F

Clinical Immunology

Volumn 137, Issue 2, 2010, Pages 271-280

  Yu, Yun Zhou ^a   Zhang, Shu Ming ^b   Ma, Yao ^a   Zhu, Heng Qi ^a   Wang, Wen Bing ^a   Du, Yun ^a   Zhou, Xiao Wei ^a   Wang, Rui Lin ^a   Wang, Shuang ^a   Yu, Wei Yuan ^a   Huang, Pei Tang ^a   Sun, Zhi Wei ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

Author keywords

Antitoxin; ; Botulinum neurotoxin; ; Botulism; ; FHc; Immunotherapy; ; Vaccine;

Indexed keywords

ANTITOXIN; BOTULINUM TOXIN F; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; PEPSIN A; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BOTULISM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG PURIFICATION; DRUG SCREENING; ESCHERICHIA COLI; FEMALE; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES; ANTIBODIES, NEUTRALIZING; BOTULINUM ANTITOXIN; BOTULINUM TOXINS; BOTULISM; CROSS REACTIONS; ESCHERICHIA COLI; HORSES; IMMUNE SERA; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; MICE; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECOMBINANT PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS; VACCINATION; VACCINES, SUBUNIT;

EID: 77957293773     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.07.005     Document Type: Article

References (34)

1. Turton K., Chaddock J.A., Acharya K.R. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem. Sci. 2002, 27:552-558.
2. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rew. 2000, 80:717-766.
3. Dembek Z.F., Smith L.A., Rusnak J.M. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med. Public Health Prep. 2007, 1:122-134.
4. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Fine A.D., Hauer J., Layton M., Lillibridge S., Osterholm M.T., O'Toole T., Parker G., Perl T.M., Russell P.K., Swerdlow D.L., Tonat K. Botulinum toxin as a biological weapon. JAMA 2001, 285:1059-1070. Working Group on Civilian Biodefense.
5. Byrne M.P., Smith L.A. Development of vaccines for prevention of botulism. Biochimie 2000, 82:955-966.
6. Hassani M., Patel M.C., Pirofskia L. Vaccines for the prevention of diseases caused by potential bioweapons. Clin. Immunol. 2004, 111:1-15.
7. Middlebrook J.L. Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology. Adv. Drug Deliv. Rev. 2005, 57:1415-1423.
8. Smith L.A., Rusnak J.M. Botulinum neurotoxin vaccines: past, present, and future. Crit. Rev. Immunol. 2007, 27:303-318.
9. Casadevall A. Passive antibody therapies: progress and continuing challenges. Clin. Immunol. 1999, 93:5-15.
10. Mayer C.N., Holley J.L., Brooks T. Antitoxin therapy for botulinum intoxication. Rew. Med. Microbiol. 2001, 12:29-37.
11. Jones R.G., Alsop T.A., Hull R., Tierney R., Rigsby P., Holley J., Sesardic D. Botulinum type A toxin neutralisation by specific IgG and its fragments: a comparison of mouse systemic toxicity and local flaccid paralysis assays. Toxicon 2006, 48:246-254.
12. Clayton M.A., Clayton J.M., Brown D.R., Middlebrook J.L. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect. Immun. 1995, 63:2728-2742.
13. Holley J.L., Elmore M., Mauchline M., Minton N., Titball R.W. Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin. Vaccine 2000, 19:288-297.
14. Woodward L.A., Arimitsu H., Hirst R., Oguma K. Expression of Hc subunits from Clostridium botulinum type C and D and their evaluation as candidate vaccine antigens in mice. Infect. Immun. 2003, 71:2941-2944.
15. Tavallaie M., Chenal A., Gillet D., Pereira Y., Manich M., Gibert M., Raffestin S., Popoff M.R., Marvaud J.C. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett. 2004, 572:299-306.
16. Baldwin M.R., Tepp W.H., Pier C.L., Bradshaw M., Ho M., Wilson B.A., Fritz R.B., Johnson E.A., Barbieri J.T. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect. Immun. 2005, 73:6998-7005.
17. Ravichandran E., Al-Saleem F.H., Ancharski D.M., Elias M.D., Singh A.K., Shamim M., Gong Y., Simpson L.L. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect. Immun. 2007, 75:3043-3054.
18. Baldwin M.R., Tepp W.H., Przedpelski A., Pier C.L., Bradshaw M., Johnson E.A., Barbieri J.T. Subunit vaccine against the seven serotypes of botulism. Infect. Immun. 2008, 76:1314-1318.
19. Yu Y.Z., Sun Z.W., Li N., Wang S., Wang R.L., Yu W.Y. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Clin. Vaccine Immunol. 2008, 15:1819-1823.
20. Stahl C., Unger L., Mazuet C., Popoff M., Straub R., Frey J. Immune response of horses to vaccination with the recombinant Hc domain of botulinum neurotoxin types C and D. Vaccine 2009, 27:5661-5666.
21. Yu Y.Z., Li N., Zhu H.Q., Wang R.L., Du Y., Wang S., Yu W.Y., Sun Z.W. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine 2009, 27:2816-2822.
22. Byrne M.P., Smith T.J., Montgomery V.A., Smith L.A. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect. Immun. 1998, 66:4817-4822.
23. Smith L.A. Development of recombinant vaccines for botulinum toxin. Toxicon 1998, 36:1539-1548.
24. Byrne M.F., Titball R.W., Holley J., Smith L.A. Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris. Protein Expr. Purif. 2000, 18:327-337.
25. Gurkan C., Ellar D.J. Recombinant production of bacterial toxins and their derivatives in the methylotrophic yeast Pichia pastoris. Microb. Cell Fact. 2005, 4:33. 10.1186/11475-2859-4-33.
26. Boles J., West M., Montgomery V., Tammariello R., Pitt M.L., Gibbs P., Smith L., LeClaire R.D. Recombinant C fragment of botulinum neurotoxin serotype B (rBoNTB(Hc)) immune response and protection in the rhesus monkey. Toxicon 2006, 47:877-884.
27. Webb R.P., Smith T.J., Wright P.M., Montgomery V.A., Meagher M.M., Smith L.A. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine 2007, 25:4273-4282.
28. Wang X., Ni B., Du X., Zhao G., Gao W., Shi X., Zhang S., Zhang L., Wang D., Luo D., Xing L., Jiang H., Li W., Jiang M., Mao L., He Y., Xiao Y., Wu Y. Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody. Antivir. Ther. 2005, 10:681-690.
29. Pharmacopoeia of the people's republic of china. Appendix XII H: The Potency Assay Of Botulinum Antitoxin 2005, Chinese Pharmacopoeia Commission, (Volume III), People's Medical Publishing House, Beijing, Appendix pp. 69-70.
30. Yu R., Wang S., Yu Y.Z., Yu W.Y., Sun Z.W. High-level and soluble expressions of botulinum neurotoxin serotype B protective antigen Hc domain in Escherichia coli. Lett. Biotechnol. 2008, 19:365-367. (in Chinese).
31. Tacket C.O., Shandera W.X., Mann J.M., Hargrett N.T., Blake P.A. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am. J. Med. 1984, 76:794-798.
32. Middlebrook J.L., Brown J.E. Immunodiagnosis and immunotherapy of tetanus and botulinum neurotoxins. Curr. Top. Microbiol. Immunol. 1995, 95:89-122.
33. Franz D.R., Jahrling P.B., Friedlander A.M., McClain D.J., Hoover D.L., Bryne W.R., Pavlin J.A., Christopher G.W., Jr Eitzen E.M. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997, 278:399-411.
34. Gelzleichter T.R., Myers M.A., Menton R.G., Niemuth N.A., Matthews M.C., Langford M.J. Protection against botulinum toxins provided by passive immunization with botulinum human immune globulin: evaluation using an inhalation model. J. Appl. Toxicol. 1999, 19:S35-S38.